BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
293.27
-11.35 (-3.73%)
At close: May 15, 2026, 4:00 PM EDT
298.00
+4.73 (1.61%)
After-hours: May 15, 2026, 7:46 PM EDT
BeOne Medicines AG Employees
BeOne Medicines AG had 12,000 employees as of March 31, 2026. The number of employees increased by 1,000 or 9.09% compared to the same quarter last year.
Employees
12,000
Change
1,000
Growth
9.09%
Revenue / Employee
$475,411
Profits / Employee
$44,478
Market Cap
32.60B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Dec 31, 2025 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Sep 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Jun 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Mar 31, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Dec 31, 2024 | 11,000 | 400 | 3.77% | 11,000 | 0 |
| Jun 30, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Mar 31, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Dec 31, 2023 | 10,600 | 1,600 | 17.78% | 10,600 | 0 |
| Mar 31, 2023 | 9,400 | 1,100 | 13.25% | 9,400 | 0 |
| Dec 31, 2022 | 9,000 | 1,000 | 12.50% | 9,000 | 0 |
| Sep 30, 2022 | 9,000 | 1,400 | 18.42% | 9,000 | 0 |
| Mar 31, 2022 | 8,300 | 2,900 | 53.70% | 8,300 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,088 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
ONC News
- 2 days ago - BeOne Medicines price target raised to $367 from $364 at Leerink - TheFly
- 4 days ago - BeOne Medicines (ONC) Receives FDA Fast-Tracked Approval for Beqalzi - GuruFocus
- 4 days ago - BeOne Medicines’ Beqalzi granted accelerated approval by FDA - TheFly
- 4 days ago - US FDA approves BeOne's drug for a type of blood cancer - Reuters
- 4 days ago - BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - Business Wire
- 4 days ago - BeOne Medicines’ BEQALZI (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - Wallstreet:Online
- 10 days ago - BeOne Medicines price target raised to $395 from $389 at Morgan Stanley - TheFly
- 10 days ago - BeOne Medicines price target raised to $409 from $405 at Barclays - TheFly